On July 2, RemeGen (09995.HK) rose 7.34% in regular trading, reaching HK$77.85 per share, with turnover of approximately HK$240 million.

On the news front, the publication of the national medical insurance negotiation preliminary review list provided a sector-wide catalyst, while company-specific dynamics further reinforced bullish sentiment. On July 1, 193 million restricted shares — representing 34.16% of total share capital — were officially unlocked. However, because the company's cash dividend distributions have not met regulatory thresholds, shareholders subject to the lock-up release are prohibited from reducing their A-share holdings through centralized bidding or block trading. This regulatory restriction means actual selling pressure is substantially lower than market expectations. On the A-share side, RemeGen surged 6.71% on July 1 with net main capital inflows of RMB 207 million, signaling rapid sentiment recovery. The broader biotechnology sector also rallied, with peers including Innovent Biologics up 6.66%, Akeso up 6.47%, and 3SBio up 8.94%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)